A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
Clinical trial NCT03685630 · COMPLETED
Trial details
- NCT number
- NCT03685630
- Sponsor
- UCB Biopharma S.P.R.L.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-04
- Primary completion
- 2021-03-27
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.